What is Ultragenyx Pharmaceutical's investing cash flow?

Ultragenyx Pharmaceutical (RARE) reported investing cash flow of -$49M in Q1 2026.

How has Ultragenyx Pharmaceutical's investing cash flow changed year-over-year?

Ultragenyx Pharmaceutical's investing cash flow decreased by 140.8% year-over-year, from $120M to -$49M.

What does investing cash flow mean?

Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ultragenyx Pharmaceutical RARE Investing Cash Flow

Investing Cash Flow at other companies

Eli LillyLLY

-$3.92B-16.8%

AmgenAMGN

-$716M-60.2%

Ionis PharmaceuticalsIONS

$536.82M+215%

Arrowhead ResearchARWR

-$894.28M-113%

CRISPR TherapeuticsCRSP

-$410.74M-1,979%

ModernaMRNA

-$76M-110%

Other financials

Income statement

See full

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

See full

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total equity-$236.0M-264%

Total assets$1.3B-1.2%

Cash flow

See full

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

See full

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

See full

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

See full

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's investing cash flow?: Ultragenyx Pharmaceutical (RARE) reported investing cash flow of -$49M in Q1 2026.
How has Ultragenyx Pharmaceutical's investing cash flow changed year-over-year?: Ultragenyx Pharmaceutical's investing cash flow decreased by 140.8% year-over-year, from $120M to -$49M.
What does investing cash flow mean?: Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.